Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

renal cell carcinoma

- PMLiVE

Merck & Co pays €110m upfront for AiCuris’ CMV portfolio

Lead candidate is orphan drug letermovir for transplant patients

- PMLiVE

Merck says osteoporosis drug clears phase II trial

Odanacatib on track for 2013 filing

- PMLiVE

Merck & Co relocates global headquarters

Leaves Whitehouse Station for new site in New Jersey

- PMLiVE

Merck & Co says Januvia follow-up looking good

Diabetes drug shows promise in phase II as once-weekly treatment

- PMLiVE

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs

Incivo and Victrelis joint winners of Innovative Product Award

- PMLiVE

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs

Incivo and Victrelis joint winners of Innovative Product Award

Merck’s new insomnia drug clears phase III trial

Novel method of treatment offers fewer side effects

- PMLiVE

Pfizer’s Inlyta gets EU approval for advanced kidney cancer

Available as second-line therapy after treatment with pharma firm's own Sutent

- PMLiVE

Pfizer dealt another blow as Torisel fails kidney cancer trial

Results are another setback in company's bid to extend the indications for its mTOR inhibitor

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links